Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Novel mouse model of indwelling pleural catheter in mice with malignant pleural effusion.

Merrick C, Sherrill T, Kanellakis NI, Asciak R, Stathopoulos GT, Maldonado F, Rahman NM, Blackwell T, Psallidas I.

ERJ Open Res. 2019 May 28;5(2). pii: 00226-2018. doi: 10.1183/23120541.00226-2018. eCollection 2019 Apr.

2.

Club cells form lung adenocarcinomas and maintain the alveoli of adult mice.

Spella M, Lilis I, Pepe MA, Chen Y, Armaka M, Lamort AS, Zazara DE, Roumelioti F, Vreka M, Kanellakis NI, Wagner DE, Giannou AD, Armenis V, Arendt KA, Klotz LV, Toumpanakis D, Karavana V, Zakynthinos SG, Giopanou I, Marazioti A, Aidinis V, Sotillo R, Stathopoulos GT.

Elife. 2019 May 29;8. pii: e45571. doi: 10.7554/eLife.45571. [Epub ahead of print]

3.

Tobacco chemical-induced mouse lung adenocarcinoma cell lines pin the prolactin orthologue proliferin as a lung tumour promoter.

Kanellakis NI, Giannou AD, Pepe MA, Αgalioti T, Zazara DE, Giopanou I, Psallidas I, Spella M, Μarazioti A, Arendt KAM, Lamort AS, Tsaniras SC, Taraviras S, Papadaki H, Lilis I, Stathopoulos GT.

Carcinogenesis. 2019 Mar 4. pii: bgz047. doi: 10.1093/carcin/bgz047. [Epub ahead of print]

PMID:
30828726
4.

Does attempting talc pleurodesis affect subsequent indwelling pleural catheter (IPC)-related non-draining septated pleural effusion and IPC-related spontaneous pleurodesis?

Asciak R, Mercer RM, Hallifax RJ, Hassan M, Bedawi E, McCracken D, Kanellakis NI, Wrightson JM, Psallidas I, Rahman NM.

ERJ Open Res. 2019 Feb 1;5(1). pii: 00208-2018. doi: 10.1183/23120541.00208-2018. eCollection 2019 Feb.

5.

Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.

Psallidas I, Kanellakis NI, Gerry S, Thézénas ML, Charles PD, Samsonova A, Schiller HB, Fischer R, Asciak R, Hallifax RJ, Mercer R, Dobson M, Dong T, Pavord ID, Collins GS, Kessler BM, Pass HI, Maskell N, Stathopoulos GT, Rahman NM.

Lancet Oncol. 2018 Jul;19(7):930-939. doi: 10.1016/S1470-2045(18)30294-8. Epub 2018 Jun 13.

PMID:
29908990
6.

IκB Kinase α Is Required for Development and Progression of KRAS-Mutant Lung Adenocarcinoma.

Vreka M, Lilis I, Papageorgopoulou M, Giotopoulou GA, Lianou M, Giopanou I, Kanellakis NI, Spella M, Agalioti T, Armenis V, Goldmann T, Marwitz S, Yull FE, Blackwell TS, Pasparakis M, Marazioti A, Stathopoulos GT.

Cancer Res. 2018 Jun 1;78(11):2939-2951. doi: 10.1158/0008-5472.CAN-17-1944. Epub 2018 Mar 27.

7.

A Pilot Feasibility Study in Establishing the Role of Ultrasound-Guided Pleural Biopsies in Pleural Infection (The AUDIO Study).

Psallidas I, Kanellakis NI, Bhatnagar R, Ravindran R, Yousuf A, Edey AJ, Mercer RM, Corcoran JP, Hallifax RJ, Asciak R, Shetty P, Dong T, Piotrowska HEG, Clelland C, Maskell NA, Rahman NM.

Chest. 2018 Oct;154(4):766-772. doi: 10.1016/j.chest.2018.02.031. Epub 2018 Mar 7.

PMID:
29524388
8.

Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion.

Marazioti A, Lilis I, Vreka M, Apostolopoulou H, Kalogeropoulou A, Giopanou I, Giotopoulou GA, Krontira AC, Iliopoulou M, Kanellakis NI, Agalioti T, Giannou AD, Jones-Paris C, Iwakura Y, Kardamakis D, Blackwell TS, Taraviras S, Spella M, Stathopoulos GT.

Nat Commun. 2018 Feb 14;9(1):672. doi: 10.1038/s41467-018-03051-z.

9.

Efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE): protocol of a randomised controlled trial.

Psallidas I, Piotrowska HEG, Yousuf A, Kanellakis NI, Kagithala G, Mohammed S, Clifton L, Corcoran JP, Russell N, Dobson M, Miller RF, Rahman NM.

BMJ Open Respir Res. 2017 Nov 20;4(1):e000225. doi: 10.1136/bmjresp-2017-000225. eCollection 2017.

10.

Mutant KRAS promotes malignant pleural effusion formation.

Agalioti T, Giannou AD, Krontira AC, Kanellakis NI, Kati D, Vreka M, Pepe M, Spella M, Lilis I, Zazara DE, Nikolouli E, Spiropoulou N, Papadakis A, Papadia K, Voulgaridis A, Harokopos V, Stamou P, Meiners S, Eickelberg O, Snyder LA, Antimisiaris SG, Kardamakis D, Psallidas I, Marazioti A, Stathopoulos GT.

Nat Commun. 2017 May 16;8:15205. doi: 10.1038/ncomms15205.

11.

NRAS destines tumor cells to the lungs.

Giannou AD, Marazioti A, Kanellakis NI, Giopanou I, Lilis I, Zazara DE, Ntaliarda G, Kati D, Armenis V, Giotopoulou GA, Krontira AC, Lianou M, Agalioti T, Vreka M, Papageorgopoulou M, Fouzas S, Kardamakis D, Psallidas I, Spella M, Stathopoulos GT.

EMBO Mol Med. 2017 May;9(5):672-686. doi: 10.15252/emmm.201606978.

12.

Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis.

Giopanou I, Lilis I, Papaleonidopoulos V, Agalioti T, Kanellakis NI, Spiropoulou N, Spella M, Stathopoulos GT.

Oncoimmunology. 2016 Nov 18;6(1):e1256528. doi: 10.1080/2162402X.2016.1256528. eCollection 2017.

13.

Targeted therapies for lung cancer: how did the game begin?

Kanellakis NI, Jacinto T, Psallidas I.

Breathe (Sheff). 2016 Jun;12(2):177-9. doi: 10.1183/20734735.006316.

14.

Whole transcriptome data analysis of mouse embryonic hematopoietic stem and progenitor cells that lack Geminin expression.

Patmanidi AL, Kanellakis NI, Karamitros D, Papadimitriou C, Lygerou Z, Taraviras S.

Data Brief. 2016 Mar 12;7:889-93. doi: 10.1016/j.dib.2016.03.028. eCollection 2016 Jun.

15.

Mast cells mediate malignant pleural effusion formation.

Giannou AD, Marazioti A, Spella M, Kanellakis NI, Apostolopoulou H, Psallidas I, Prijovich ZM, Vreka M, Zazara DE, Lilis I, Papaleonidopoulos V, Kairi CA, Patmanidi AL, Giopanou I, Spiropoulou N, Harokopos V, Aidinis V, Spyratos D, Teliousi S, Papadaki H, Taraviras S, Snyder LA, Eickelberg O, Kardamakis D, Iwakura Y, Feyerabend TB, Rodewald HR, Kalomenidis I, Blackwell TS, Agalioti T, Stathopoulos GT.

J Clin Invest. 2015 Jun;125(6):2317-34. doi: 10.1172/JCI79840. Epub 2015 Apr 27.

Supplemental Content

Loading ...
Support Center